Agnieszka Dzik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Agnieszka Dzik has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Grazyna Biala
Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Chodzki Str., 20-093 Lublin, Poland
4 shared publications - Marta Kruk-Slomka
Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Chodzki Str., 20-093 Lublin, Poland
4 shared publications - Tomasz Slomka
Department of Medical Informatics and Statistics with E-Health Lab, Medical University of Lublin, Jaczewskiego 4 Street, 20-954 Lublin, Poland
1 shared publication
Latest Publications
- Open Access
- 4 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1574
Effects of Endocannabinoid System Modulation on Cholinergic-Induced Anxiety-like Behaviors in Mice
Background: Anxiety disorders are clinically significant non-cognitive symptoms of many neuropsychiatric disorders, often accompanying progressive memory deficits and reflecting neurochemical dysregulation, particularly cholinergic dysfunction. Current therapy for these disorders is focused on the memory deficits but does not improve emotional symptoms and may even worsen anxiety. Therefore, novel therapeutic strategies are needed that address both cognitive and non-cognitive symptoms. Aim: Recent studies suggest that the endocannabinoid system (ECS) may play a key role in regulating cognitive and emotional processes, including anxiety. The aim of the study was to evaluate how direct (via selective ligands of cannabinoid CB1 and CB2 receptors) and indirect (via inhibitors of endocannabinoid-degrading enzymes—fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)) modulation of ECS activity affects anxiety-like behaviors induced by pharmacological modification of cholinergic neurotransmission (by using nicotine or scopolamine). Methods: Anxiety-related behaviors were assessed in mice using the elevated plus maze (EPM) test. Results: CB1 receptor agonist oleamide (5 mg/kg), FAAH inhibitor URB 597 (0.1 mg/kg), and MAGL inhibitor JZL 184 (20 mg/kg) attenuated the anxiogenic effects of nicotine (0.1 mg/kg). Additionally, oleamide (5 mg/kg), CB1/CB2 receptor agonist WIN 55,212-2 (0.25 mg/kg), CB2 receptor antagonist AM 630 (0.25 mg/kg), and JZL 184 (20 mg/kg) attenuated the anxiogenic effects induced by scopolamine (1 mg/kg). Conclusions: Both direct and indirect ECS modulation demonstrated an impact on anxiety-like responses induced by cholinergic ligands. This potential relationship between ECS and cholinergic pathways provides additional insights into anxiety regulation and may represent a promising starting point for further research into targeted anxiolytic mechanisms in the central nervous system (CNS).
- 4 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1574
Open AccessEffects of Endocannabinoid System Modulation on Cholinergic-Induced Anxiety-like Behaviors in Mice
Background: Anxiety disorders are clinically significant non-cognitive symptoms of many neuropsychiatric disorders, often accompanying progressive memory deficits and reflecting neurochemical dysregulation, particularly cholinergic dysfunction. Current therapy for these disorders is focused on the memory deficits but does not improve emotional symptoms and may even worsen anxiety. Therefore, novel therapeutic strategies are needed that address both cognitive and non-cognitive symptoms. Aim: Recent studies suggest that the endocannabinoid system (ECS) may play a key role in regulating cognitive and emotional processes, including anxiety. The aim of the study was to evaluate how direct (via selective ligands of cannabinoid CB1 and CB2 receptors) and indirect (via inhibitors of endocannabinoid-degrading enzymes—fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)) modulation of ECS activity affects anxiety-like behaviors induced by pharmacological modification of cholinergic neurotransmission (by using nicotine or scopolamine). Methods: Anxiety-related behaviors were assessed in mice using the elevated plus maze (EPM) test. Results: CB1 receptor agonist oleamide (5 mg/kg), FAAH inhibitor URB 597 (0.1 mg/kg), and MAGL inhibitor JZL 184 (20 mg/kg) attenuated the anxiogenic effects of nicotine (0.1 mg/kg). Additionally, oleamide (5 mg/kg), CB1/CB2 receptor agonist WIN 55,212-2 (0.25 mg/kg), CB2 receptor antagonist AM 630 (0.25 mg/kg), and JZL 184 (20 mg/kg) attenuated the anxiogenic effects induced by scopolamine (1 mg/kg). Conclusions: Both direct and indirect ECS modulation demonstrated an impact on anxiety-like responses induced by cholinergic ligands. This potential relationship between ECS and cholinergic pathways provides additional insights into anxiety regulation and may represent a promising starting point for further research into targeted anxiolytic mechanisms in the central nervous system (CNS).
- Open Access
The Effects of Indirect and Direct Modulation of Endocannabinoid System Function on Anxiety-Related Behavior in Mice Assessed in the Elevated Plus Maze Test
Background: The endocannabinoid system (ECS) is one of the most important systems modulating functions in the body. The ECS, via cannabinoid (CB: CB1 and CB2) receptors, endocannabinoids occurring in the brain (e.g., anandamide (AEA) and 2-arachidonoylglycerol (2-AG)) and enzymes degrading endocannabinoids in the brain (fatty-acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)), plays a key role in the regulation of mood and anxiety. However, the effects of cannabinoid compounds on anxiety-related responses are complex and yield mixed results depending on the type of pharmacological manipulation (direct or indirect) of functions of the ECS, as well as the kinds of cannabinoids, dosage and procedure. Methods: The aim of this study was to determine and compare the influence of the direct (via CB receptors ligands) and indirect (via inhibition of enzymes degrading endocannabinoids in the brain) pharmacological modulation of ECS function on anxiety-like responses in mice in the elevated plus maze (EPM) test. For this purpose, in the first step of the experiments, we used selected ligands of CB1, CB1/CB2 and CB2 receptors to assess which types of CB receptors are involved in anxiety-related responses in mice. Next, we used inhibitors of FAAH (which breaks down AEA) or MAGL (which breaks down 2-AG) to assess which endocannabinoid is more responsible for anxiety-related behavior in mice. Results: The results of our presented research showed that an acute administration of CB1 receptor agonist oleamide (5–20 mg/kg) had no influence on anxiety-related responses and CB1 receptor antagonist AM 251 (0.25–3 mg/kg) had anxiogenic effects in the EPM test in mice. In turn, an acute administration of mixed CB1/CB2 receptor agonist WIN55,212-2 used at a dose of 1 mg/kg had an anxiolytic effect observed in mice in the EPM test. What is of interest is that both the acute administration of a CB2 receptor agonist (JWH 133 at the doses of 1 and 2 mg/kg) and antagonist (AM 630 at the doses of 0.5–2 mg/kg) had anxiogenic effects in this procedure. Moreover, we revealed that an acute administration of only FAAH inhibitor URB 597 (0.3 mg/kg) had an anxiolytic effect, while MAGL inhibitor JZL 184 (at any used doses (2–40 mg/kg)) after an acute injection had no influence on anxiety behavior in mice, as observed in the EPM test. Conclusions: In our experiments, we confirmed the clearly significant involvement of the ECS in anxiety-related responses. In particular, the pharmacological indirect manipulation of ECS functions is able to elicit promising anxiolytic effects. Therefore, the ECS could be a potential target for novel anxiolytic drugs; however, further studies are needed.
Open AccessThe Effects of Indirect and Direct Modulation of Endocannabinoid System Function on Anxiety-Related Behavior in Mice Assessed in the Elevated Plus Maze Test
Background: The endocannabinoid system (ECS) is one of the most important systems modulating functions in the body. The ECS, via cannabinoid (CB: CB1 and CB2) receptors, endocannabinoids occurring in the brain (e.g., anandamide (AEA) and 2-arachidonoylglycerol (2-AG)) and enzymes degrading endocannabinoids in the brain (fatty-acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)), plays a key role in the regulation of mood and anxiety. However, the effects of cannabinoid compounds on anxiety-related responses are complex and yield mixed results depending on the type of pharmacological manipulation (direct or indirect) of functions of the ECS, as well as the kinds of cannabinoids, dosage and procedure. Methods: The aim of this study was to determine and compare the influence of the direct (via CB receptors ligands) and indirect (via inhibition of enzymes degrading endocannabinoids in the brain) pharmacological modulation of ECS function on anxiety-like responses in mice in the elevated plus maze (EPM) test. For this purpose, in the first step of the experiments, we used selected ligands of CB1, CB1/CB2 and CB2 receptors to assess which types of CB receptors are involved in anxiety-related responses in mice. Next, we used inhibitors of FAAH (which breaks down AEA) or MAGL (which breaks down 2-AG) to assess which endocannabinoid is more responsible for anxiety-related behavior in mice. Results: The results of our presented research showed that an acute administration of CB1 receptor agonist oleamide (5–20 mg/kg) had no influence on anxiety-related responses and CB1 receptor antagonist AM 251 (0.25–3 mg/kg) had anxiogenic effects in the EPM test in mice. In turn, an acute administration of mixed CB1/CB2 receptor agonist WIN55,212-2 used at a dose of 1 mg/kg had an anxiolytic effect observed in mice in the EPM test. What is of interest is that both the acute administration of a CB2 receptor agonist (JWH 133 at the doses of 1 and 2 mg/kg) and antagonist (AM 630 at the doses of 0.5–2 mg/kg) had anxiogenic effects in this procedure. Moreover, we revealed that an acute administration of only FAAH inhibitor URB 597 (0.3 mg/kg) had an anxiolytic effect, while MAGL inhibitor JZL 184 (at any used doses (2–40 mg/kg)) after an acute injection had no influence on anxiety behavior in mice, as observed in the EPM test. Conclusions: In our experiments, we confirmed the clearly significant involvement of the ECS in anxiety-related responses. In particular, the pharmacological indirect manipulation of ECS functions is able to elicit promising anxiolytic effects. Therefore, the ECS could be a potential target for novel anxiolytic drugs; however, further studies are needed.
- Open Access
- 3 January 2025
- Published by MDPI AG in Preprints.org
The Effects of Indirect and Direct Modulation of Endocannabinoid System Function on Anxiety-Related Behavior in Mice Assessed in the Elevated Plus Maze Test
Background: Endocannabinoid system (ECS) via cannabinoid (CB: CB1 and CB2) receptors and enzymes degrading endocannabinoids in the brain (atty-acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), plays a key role in regulation of mood and anxiety. However, the effects of cannabinoid compounds on anxiety-related responses is complex and yield mixed results depending on the type of pharmacological manipulation (direct or indirect) of functions of ECS, as well as kind of cannabinoids, dosage and procedure. Methods: The aim of the study was to determine and compare the influence of the direct (via CB receptors ligands) and indirect (via inhibition of enzymes degrading endocannabinoids in the brain) pharmacological modulation of ECS function on the anxiety-like responses in mice in the elevated plus maze (EPM) test. For this purpose, in the first step of experiments we used selected ligands of CB1, CB1/CB2 and CB2 receptors to asses which type of CB receptors is involved in the anxiety-related responses in mice. Next, we used inhibitors of FAAH or MAGL to assess which enzyme is more responsible for anxiety-related behavior in mice. Results: The results of our presented research showed that an acute administration of CB1 receptor agonist – oleamide (5-20 mg/kg) had no influence on anxiety-related responses and CB1 receptor antagonist – AM 251 had anxiogenic (0.25-3 mg/kg) effects in the EPM test in mice. In turn, an acute administration of CB1/CB2 receptor agonist - WIN55,212-2 used at a dose of 1 mg/kg, had an anxiolytic effect observed in mice in the EPM test. What is of interest, both acute administration of CB2 receptor agonist (JWH 133 at the doses of 1 and 2 mg/kg) and antagonist (AM 630 at the doses of 0.5-2 mg/kg) had anxiogenic effects in this procedure. Moreover, we revealed that an acute administration of only FAAH inhibitor - URB 597 (0.3 mg/kg) had anxiolytic effect, while MAGL inhibitor (JZL 184) after an acute injection had no influence on anxiety behavior in mice observed in the EPM. Conclusion: In our experiments we confirmed the significant involvement of the ECS in anxiety-related responses. Both pharmacological indirect and direct (mainly through the CB1 receptors) manipulation of ECS functions is able to elicit promising anxiolytic effects. Therefore, ECS could be a potential target for novel anxiolytic drugs; however the further studies are needed.
- 3 January 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Effects of Indirect and Direct Modulation of Endocannabinoid System Function on Anxiety-Related Behavior in Mice Assessed in the Elevated Plus Maze Test
Background: Endocannabinoid system (ECS) via cannabinoid (CB: CB1 and CB2) receptors and enzymes degrading endocannabinoids in the brain (atty-acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), plays a key role in regulation of mood and anxiety. However, the effects of cannabinoid compounds on anxiety-related responses is complex and yield mixed results depending on the type of pharmacological manipulation (direct or indirect) of functions of ECS, as well as kind of cannabinoids, dosage and procedure. Methods: The aim of the study was to determine and compare the influence of the direct (via CB receptors ligands) and indirect (via inhibition of enzymes degrading endocannabinoids in the brain) pharmacological modulation of ECS function on the anxiety-like responses in mice in the elevated plus maze (EPM) test. For this purpose, in the first step of experiments we used selected ligands of CB1, CB1/CB2 and CB2 receptors to asses which type of CB receptors is involved in the anxiety-related responses in mice. Next, we used inhibitors of FAAH or MAGL to assess which enzyme is more responsible for anxiety-related behavior in mice. Results: The results of our presented research showed that an acute administration of CB1 receptor agonist – oleamide (5-20 mg/kg) had no influence on anxiety-related responses and CB1 receptor antagonist – AM 251 had anxiogenic (0.25-3 mg/kg) effects in the EPM test in mice. In turn, an acute administration of CB1/CB2 receptor agonist - WIN55,212-2 used at a dose of 1 mg/kg, had an anxiolytic effect observed in mice in the EPM test. What is of interest, both acute administration of CB2 receptor agonist (JWH 133 at the doses of 1 and 2 mg/kg) and antagonist (AM 630 at the doses of 0.5-2 mg/kg) had anxiogenic effects in this procedure. Moreover, we revealed that an acute administration of only FAAH inhibitor - URB 597 (0.3 mg/kg) had anxiolytic effect, while MAGL inhibitor (JZL 184) after an acute injection had no influence on anxiety behavior in mice observed in the EPM. Conclusion: In our experiments we confirmed the significant involvement of the ECS in anxiety-related responses. Both pharmacological indirect and direct (mainly through the CB1 receptors) manipulation of ECS functions is able to elicit promising anxiolytic effects. Therefore, ECS could be a potential target for novel anxiolytic drugs; however the further studies are needed.
- Open Access
The Influence of CB2-Receptor Ligands on the Memory-Related Responses in Connection with Cholinergic Pathways in Mice in the Passive Avoidance Test
Background: Dysfunction of the cholinergic system is associated with the development of Alzheimer’s disease (AD). One of the new possible strategies for the pharmacological modulation of memory-related problems typical of AD, is connected with the endocannabinoid system (ECS) and the cannabinoid (CB: CB1 and CB2) receptors. Methods: The aim of the study was to determine the influence of the selective CB2 receptor ligands: agonist (JWH 133) and antagonist (AM 630) on different stages of memory and learning in mice, in the context of their interaction with cholinergic pathways. To assess and understand the memory-related effects in mice we used the passive avoidance (PA) test. Results: We revealed that co-administration of non-effective dose of JWH 133 (0.25 mg) or AM 630 (0.25 mg/kg) with the non-effective dose of cholinergic receptor agonist - nicotine (0.05 mg/kg) enhanced cognition in the PA test in mice; however, an acute injection of JWH 133 (0.25 mg/kg) or AM 630 (0.25 mg/kg) had no influence on memory enhancement induced by the effective dose of nicotine (0.1 mg/kg). Co-administration of JWH 133 (0.25 mg) or AM 630 (0.25 mg/kg) with the effective dose of the cholinergic receptor antagonist scopolamine (1 mg/kg) attenuated the scopolamine-induced memory impairment in the PA test in mice. Conclusion: Our experiments have shown that CB2 receptors participate in the modulation of memory-related responses, especially those in which cholinergic pathways are implicated.
Open AccessThe Influence of CB2-Receptor Ligands on the Memory-Related Responses in Connection with Cholinergic Pathways in Mice in the Passive Avoidance Test
Background: Dysfunction of the cholinergic system is associated with the development of Alzheimer’s disease (AD). One of the new possible strategies for the pharmacological modulation of memory-related problems typical of AD, is connected with the endocannabinoid system (ECS) and the cannabinoid (CB: CB1 and CB2) receptors. Methods: The aim of the study was to determine the influence of the selective CB2 receptor ligands: agonist (JWH 133) and antagonist (AM 630) on different stages of memory and learning in mice, in the context of their interaction with cholinergic pathways. To assess and understand the memory-related effects in mice we used the passive avoidance (PA) test. Results: We revealed that co-administration of non-effective dose of JWH 133 (0.25 mg) or AM 630 (0.25 mg/kg) with the non-effective dose of cholinergic receptor agonist - nicotine (0.05 mg/kg) enhanced cognition in the PA test in mice; however, an acute injection of JWH 133 (0.25 mg/kg) or AM 630 (0.25 mg/kg) had no influence on memory enhancement induced by the effective dose of nicotine (0.1 mg/kg). Co-administration of JWH 133 (0.25 mg) or AM 630 (0.25 mg/kg) with the effective dose of the cholinergic receptor antagonist scopolamine (1 mg/kg) attenuated the scopolamine-induced memory impairment in the PA test in mice. Conclusion: Our experiments have shown that CB2 receptors participate in the modulation of memory-related responses, especially those in which cholinergic pathways are implicated.